The well-known biologic anti-EGFR agents, such as cetuximab, and panitumumab, consistently execute poor efficacy for RAS and RAF mutant CRC tumors, leading to the indispensability of testing KRAS and NRAS, and BRAF mutations before considering the anti-EGFR therapies [5, 68] (Fig. 1). This evidence concerns the gene EGFR and colorectal carcinoma.